Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Immunogenicity and Safety of an MF59™- Adjuvanted Trivalent Influenza Vaccine and a Non-adjuvanted Trivalent Influenza Vaccine Among Children in Senegal

NCT01819155 is registered in ClinicalTrials.gov with PATH as lead sponsor.

NCT NCT01819155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01819155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Immunogenicity and Safety of an MF59™- Adjuvanted Trivalent Influenza Vaccine and a Non-adjuvanted Trivalent Influenza Vaccine Among Children in Senegal
Lead sponsor
PATH
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2013
Completion date
September 30, 2013
Enrollment
296 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza